Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...

Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat ...

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your ...

Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...

On Tuesday, Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00.

On Tuesday, Goldman Sachs (NYSE:GS) initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6 ...

7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides ...